In 2008, LC launched its first Global Patient Survey on Lymphomas & CLL (GPS). It has been conducted every two years since. The survey seeks to understand patient experience in lymphomas as well as the impact of treatment and care. LC and its global members use results to ensure patient voices are heard, to drive planning, actions and support.
The 2020 GPS had two streams – one for patients and one for caregivers. There was an excellent response, with 11,878 responses globally comprised of 9,179 patients and 2,699 caregivers. 18 countries had over 100 responses, and member organisations within these countries are provided with this data to help them in their own planning and advocacy work. Separate reports were also created for cutaneous lymphomas, chronic lymphocytic leukaemia (CLL) and Waldenstrom’s macroglobulinemia.
The following reports are available:
Survey data has been used for posters and presentations at a number of scientific conferences.
To review results from past year’s surveys, please contact the Marketing Coordinator.